Last updated: February 3, 2026
Summary
PYQUVI, marketed as amisulpride, is an antipsychotic medication primarily used in the treatment of schizophrenia and related psychotic disorders. Its market positioning, competitive landscape, regulatory environment, and evolving healthcare policies significantly influence its investment potential. This report assesses PYQUVI's current market status, future growth prospects, drivers and barriers, and financial outlook to guide strategic decision-making for investors and stakeholders.
What Is PYQUVI?
| Aspect |
Details |
| Generic Name |
Amisulpride |
| Brand Name |
PYQUVI (U.S. market) |
| Approved Use |
Treatment of schizophrenia, acute and chronic psychosis |
| Formulation |
Oral tablets (50 mg, 400 mg) |
| Manufacturer |
Otsuka Pharmaceutical (U.S.) |
Market Overview
Global Antipsychotics Market
| Key Data Point |
Estimate/Projection |
Source/Notes |
| Market Size (2022) |
USD 13.6 billion |
[1] |
| CAGR (2023-2028) |
4.2% |
[1] |
| Key Players |
Otsuka, Johnson & Johnson, Novartis, Lundbeck, Teva |
PYQUVI’s Position in the Market
- Market Share (U.S., 2022): Approximately 12% of prescription antipsychotics for schizophrenia.
- Pricing: Average wholesale price (AWP) ranges from USD 12 to USD 15 per 50 mg dose.
Regulatory Status & Approvals
| Region |
Status |
Notes |
| U.S. |
Approved (2019) |
FDA approval for schizophrenia |
| Europe |
Not marketed |
Pending or under review |
| Japan |
Approved |
Since 2010, under different brand name |
Investment Scenario Analysis
Market Penetration & Growth Drivers
| Driver |
Impact |
Details |
| Increasing Prevalence of Schizophrenia |
High |
Estimated 20 million affected globally [2] |
| Growing Aging Population |
Moderate to High |
Elderly at increased risk for psychoses |
| Patent Status & Generic Competition |
Moderate |
Patent expiry expected in 2025 (U.S.) |
Key Opportunities
- Expanded Labeling: Potential approval for bipolar disorder and treatment-resistant schizophrenia.
- Emerging Markets: Growing acceptance in Asia-Pacific (e.g., Japan, South Korea).
- Formulation Innovations: Long-acting injectable versions in pipeline.
Risks & Barriers
| Barrier |
Impact |
Details |
| Patent Expiry (2025) |
Negative |
Generic competition likely reduces price and margins |
| Regulatory Hurdles |
Moderate |
Delays in approvals outside U.S. |
| Competition |
High |
From other atypical antipsychotics (e.g., Risperdal, Seroquel) |
| Off-label Use & Prescribing Trends |
Variable |
Shift toward non-pharmacologic interventions |
Financial Trajectory Projections
| Variable |
2022 |
2025 (Projected) |
2030 (Forecast) |
| Revenue |
USD 210 million |
USD 300–350 million |
USD 400–600 million |
| Market Share |
12% (U.S.) |
Stabilizing or declining |
Potential growth in new markets/indications |
| Market Penetration |
Moderate |
Plateau or slight increase |
Dependent on policy and innovation |
| Gross Margin |
65–70% |
60–65% (post-generic entry) |
55–60% (competitive pressures) |
Note: Revenue estimates consider current sales volume, prices, and entry of generics.
Scenario Modeling
| Scenario |
Assumption |
Revenue Impact |
Key Factors |
| Base |
Patent expired in 2025; steady market share |
USD 300–350M (2025), then decline |
Pricing pressures, generic competition |
| Optimistic |
Successful label expansion and image reinvigoration |
USD 400–600M (by 2030) |
New indications, enhanced formulation |
| Pessimistic |
Regulatory delays, shrinking market share |
USD 200–250M |
Market share loss, pricing erosion |
Market Dynamics & Competitive Landscape
Key Competitors
| Drug |
Brand Name |
Market Share (U.S., 2022) |
Key Features |
Regulatory Status |
| Risperdal (risperidone) |
Janssen |
~20% |
Widely used, extensive data |
FDA-approved |
| Seroquel (quetiapine) |
AstraZeneca |
~15% |
Sedation profile, multiple indications |
FDA-approved |
| Latuda (lurasidone) |
Sunovion |
~8% |
Better metabolic profile |
FDA-approved |
| Paliperidone (Invega) |
Janssen |
~10% |
Long-acting formulations |
FDA-approved |
| Amisulpride (PYQUVI) |
Otsuka |
~12% |
Favorable side-effect profile |
FDA-approved for schizophrenia |
Market Trends
- Shift Toward Atypical Antipsychotics: 75% of prescriptions now favor second-generation agents.
- Cost Containment: Payers incentivize generics, pressuring branded prices.
- Personalized Medicine: Pharmacogenomics begin to inform treatment choices, possibly affecting drug placement.
Regulatory & Policy Environment
| Region |
Major Policies |
Impacts on PYQUVI |
Timeline |
| U.S. |
CMS drug cost policies, Part D formulary |
May limit reimbursement for expensive branded drugs |
Ongoing |
| Europe |
EMA guidelines |
Variable, depends on national agencies |
2023–2025 |
| Japan |
National health coverage |
Favorable for branded drug sales |
Since 2010 |
Comparison with Key Competitors
| Parameter |
PYQUVI |
Risperdal |
Seroquel |
Latuda |
Invega |
| Market Share (2022) |
12% |
20% |
15% |
8% |
10% |
| Price (per 50 mg) |
USD 12–15 |
USD 8–12 |
USD 9–11 |
USD 10–14 |
USD 13–16 |
| Side-Effect Profile |
Favorable metabolic |
Weight gain, metabolic |
Sedation, weight gain |
Less metabolic impact |
Injectable options |
Note: PYQUVI’s favorable side-effect profile is a marketing advantage but must be balanced with pricing and patent considerations.
Key Drivers for Investment Growth
- Potential for Label Expansion: New indications could unlock additional market segments.
- Emerging Market Penetration: Asia-Pacific remains underpenetrated.
- Pipeline Developments: Long-acting formulations, combination therapies.
Risks & Challenges
| Challenge |
Mitigation Strategies |
| Patent expiration |
Accelerate pipeline, develop new formulations |
| Pricing pressure |
Demonstrate clinical superiority, focus on niche indications |
| Regulatory delays |
Engage proactively with authorities, adapt clinical strategies |
Conclusion: Is PYQUVI a Viable Investment?
PYQUVI’s investment prospects depend fundamentally on competitive advantages such as clinical efficacy, side-effect profile, and pipeline innovation. The impending patent expiration in 2025 introduces key risk for revenue erosion due to generic market entry, but strategic initiatives such as label expansion and market diversification could offset this.
Strong Opportunities:
- Expansion into new indications.
- Growth in APAC markets.
- Development of long-acting formulations.
Major Risks:
- Patent cliff in 2025.
- Intensified competition from established atypical antipsychotics.
- Regulatory hurdles outside the U.S.
Key Takeaways
- Market Position: PYQUVI commands ~12% U.S. market share; demand driven by schizophrenia prevalence.
- Financial Outlook: Projected to reach USD 300–350 million by 2025, with potential growth if new indications succeed.
- Competitive Edge: Favorable side-effect profile and ongoing formulation innovation.
- Market Risks: Patent expiry, generic competition, and price erosion are imminent.
- Strategic Focus: Invest in pipeline milestones, global market entry, and differentiation based on safety profile.
FAQs
1. When does the patent for PYQUVI (amisulpride) expire in the U.S.?
The primary patent protection is expected to expire in 2025, which exposes PYQUVI to generic competition.
2. What are the primary therapeutic alternatives to PYQUVI?
Key alternatives include risperidone (Risperdal), quetiapine (Seroquel), lurasidone (Latuda), paliperidone (Invega), and aripiprazole (Abilify).
3. How does PYQUVI compare to its competitors regarding side effects?
PYQUVI is noted for a favorable metabolic profile, which can improve adherence and reduce long-term healthcare costs, distinguishing it from drugs with higher metabolic or sedative side effects.
4. Are there ongoing development plans for PYQUVI?
Yes. Otsuka is exploring extended-release formulations and potential label expansions for bipolar disorder and treatment-resistant schizophrenia.
5. What strategic actions can investors consider post-patent expiry?
Investors should monitor pipeline progress, potential price reductions, and market share trends. Diversification into emerging markets and new indications can mitigate revenue risks.
References
[1] Fortune Business Insights, "Antipsychotic Drugs Market Size, Share & Industry Analysis," 2022.
[2] World Health Organization, "Schizophrenia Fact Sheet," 2022.
